SYNGAP1-related disorder

CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1

WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...

By cGxPwire Editor
September 10, 2026

Bio-Pharma

CAMP4 Therapeutics Receives Australian Clearance for First-in-Human CMP-002 Trial

CAMBRIDGE, Mass., July 27, 2026 CAMP4 Therapeutics announced that it has received regulatory clearance from Australia’s Therapeutic Goods Administration...

By cGxPwire Editor
July 28, 2026

We work Hard to get you posted with latest updates

Unwrap our new Directory

SYNGAP1-related disorder

CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1

CAMP4 Therapeutics Receives Australian Clearance for First-in-Human CMP-002 Trial